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Kiyotake Ishikawa, MD, Roger J. Hajjar, MDS ince its inception (1), clinical gene therapy hasprogressed substantially albeit slowly. Therecent development of adeno-associated virus
(AAV) vectors has galvanized the ﬁeld of gene therapy.
These vectors have important characteristics that
make them safe and efﬁcacious in various disease
states. AAV vectors induce long-term and efﬁcient
in vivo gene transduction in various organs, they do
not produce a strong immune response, and they do
not integrate in the host DNA. Their ability to trans-
duce the quiescent cells offers signiﬁcant advantages
over other gene therapy vectors for treating various
diseases (2). The recent success of clinical trials for
Leber congenital amaurosis and hemophilia using re-
combinant AAV vectors has led to an increase in clin-
ical translation of AAV-based gene therapy, including
in cardiovascular diseases. Another important feature
of AAV vectors is that there are several serotypes with
each serotype having tropism to speciﬁc organs. Many
researchers are now consistently reporting efﬁcacy of
AAV-mediated cardiac gene therapy in clinically rele-
vant animal models using their own gene targets and
delivery methods (3).SEE PAGES 139 AND 154In this issue of the Journal, 2 studies used gene
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disclose.actions have been well characterized in the cardio-
vascular system. Heme oxygenase (HO)-1, a target
protein in Hinkel et al. (4), was ﬁrst identiﬁed in
1968 (5), and this factor has been under continuous
investigation ever since in many organs throughout
the body. On the other hand, vascular endothelial
growth factor (VEGF)-B, evaluated in Woitek et al.
(6), was ﬁrst reported in 1996 (7,8), nearly 10 years
after the discovery of VEGF. This factor attracted
relatively little attention during the following years
and its function remained incompletely deﬁned.
Recent advances in gene manipulation techniques
and genetic analysis revealed detailed information
on the roles of these proteins in the heart. It seems
both HO-1 and VEGF-B have cardioprotective effects
and accordingly, a gene overexpression approach
was tested in large animal models of cardiac
diseases using a cardiotropic AAV serotype 9.
Hinkel et al. (4) focused on the anti-inﬂammatory
proﬁle of HO-1, evaluating the efﬁcacy of HO-1 over-
expression in the setting of ischemia-reperfusion
injury. Although several drugs are reported to
induce HO-1 activation and alleviate reperfusion
injury (9), gene therapy holds an advantage of acti-
vating HO-1 speciﬁcally and, potentially, more effec-
tively. In line with previous studies reporting the
beneﬁcial effects of HO-1 in protecting the heart from
cardiac ischemia (10), the authors demonstrated the
efﬁcacy of AAV-mediated HO-1 overexpression for the
ﬁrst time in large animals. The study reports a sig-
niﬁcant reduction in infarct volume in HO-1 overex-
pressed pigs along with preserved left ventricular
ejection fraction after 60 min of balloon-induced
ischemia followed by reperfusion. Although the
authors only examined the animals 24 h after the
ischemia-reperfusion injury, HO-1 has been shown to
be protective even with permanent coronary occlu-
sion (11) and also inhibits cardiac remodeling at the
chronic stages (12). Thus, a longer-term follow-up
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167may have shown further beneﬁt in the setting of
AAV’s long-term gene transduction.
In the second study, Woitek et al. (6) focus on an
isoform of VEGF with a distinctive proﬁle among its
family. VEGF-B expression is highest in the heart
and has only weak angiogenic effects in contrast to
other VEGFs (13). This protein seems to be a critical
prosurvival factor for vascular cells (14) and has
similar protective effects on cardiomyocytes (15).
AAV-mediated mouse VEGF-B167 gene transfer pre-
served cardiac function and prevented the elevation
of left ventricular end-diastolic pressure in a dog
model of tachy-pacing induced heart failure (6).
Their work was an extension of a previous study by
the same group using a similar animal model (16).FIGURE 1 Cardiac Gene Therapy Approaches Using AAV
Depending on the genes of interest, targeted phases of diseases differ. C
disease by gene transfer of down-regulated proteins, whereas the preve
et al. (6) in this issue of the Journal. AAV ¼ adeno-associated virus; HO
inhibitor 1; S100A1 ¼ calcium binding protein; SERCA2a ¼ cardiac sarco
growth factor.The authors modiﬁed the AAV delivery method to a
more clinically practical intracoronary injection and
also tested this approach in dogs that were already
developing heart failure. Strikingly, VEGF-B167 gene
transfer at the middle of the pacing protocol ex-
hibited substantial preservation of left ventricular
ejection fraction and lowered end-diastolic pressure
in the dogs receiving AAV9.VEGF-B167. Although
these results in a canine model of tachycardia-
induced heart failure are encouraging, this is a
model with relatively acute disease progression that
decompensates within 28 days. For future clinical
applications, further studies are necessary to vali-
date this therapy in more chronic models, using
human VEGF-B167.onventional gene therapy mostly focuses on correcting the developed
ntive approach is taken in the studies by Hinkel et al. (4) and Woitek
-1 ¼ heme oxygenase-1; I-1c ¼ active form of protein phosphatase
plasmic reticulum Ca2þ ATPase pump; VEGF ¼ vascular endothelial
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168The 2 studies are inherently different from con-
ventional cardiac gene therapy approaches that aim
to correct down-regulated/up-regulated genes in
already developed diseases (Figure 1). Corrective
therapies have included gene transfer of calcium
cycling protein including the cardiac sarcoplasmic
reticulum Ca2þ ATPase pump (SERCA2a), the calcium
binding protein S100A1, and the active form of pro-
tein phosphatase inhibitor 1 (I-1c) (17). Preventive
therapies require treatment before disease progres-
sion because of the nature of the targeted genes. Both
HO-1 and VEGF-B167 were effective at halting pro-
gression of disease when administered before or at
the time of injury. Although disease prevention is
generally more efﬁcient and effective compared with
disease reversal, with current technology, it is very
difﬁcult to accurately predict whether or not an in-
dividual patient will deteriorate. Advances in patient
screening methods to identify high-risk proﬁles, such
as genetic screening or induced-pluripotent stem
cell–mediated screening, may increase the value of
these preventive gene therapies.
Unlike targeting genes already down-regulated
in the disease setting, preventive gene therapy ren-
ders up-regulation of genes that are not usually
activated in the normal setting. This may lead to un-
expected results in humans where complex molecular
interactions are present and potentially longer expo-
sure to the overexpressed genes comparedwith animalstudies. One very interesting approach used byWoitek
et al. (6) is the disease-induced gene overexpression
using an atrial natriuretic factor promoter. Inducible
transgene regulation is extremely attractive because
the gene expression can be controlled depending on
the disease activity, and can also be speciﬁc to the
target organs. The atrial natriuretic factor promoter
would therefore turn onwhen the cardiacmyocyte is in
distress and be turned offwhen themyocyte is healthy.
A current limitation may be the lower transduction
efﬁcacy as the authors reported, requiring a large
amount of vectors that might induce a T-cell response
in some of the patients.
Despite the remaining issues that need to be solved
before clinical translation occurs, therapeutic efﬁ-
cacies demonstrated in these 2 gene transfer studies
using large animal models show that AAV-mediated
cardiac gene therapy is maturing for clinical applica-
tions. Advances in vector technology and gene de-
livery methods offer overexpression of not only novel
molecular targets but also well-known targets. It may
be time to look back at some of the therapeutic targets
with “obsolete” labels.
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